Nvidia, the chipmaker at the center of the AI boom, just released its quarterly results. Follow our live coverage here.
CNBC's Becky Quick reports on the progress of KJ Muldoon, the first patient to receive a personalized CRISPR-based gene ...
New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 ...
Investor's Business Daily on MSN
Gilead bets big on new drug with $7.8 billion deal as it takes on J&J
Gilead Sciences is buying Arcellx for $7.8 billion. The companies are already working together on a multiple myeloma drug.
The FDA guidelines aim to create a new pathway for bespoke therapies due to the challenges of conducting large studies.
The U.S. Food and Drug Administration issued draft guidance on Monday for sponsors seeking approval for targeted individualized therapies when randomized controlled trials are not feasible due to ...
The past few years have been challenging for the biotech.
One of the most promising is its cardiovascular disease therapy candidate CTX310, a single-treatment gene therapy that has ...
Cathie Wood's ARK Invest bought Recursion Pharmaceuticals and CRISPR Therapeutics while selling PagerDuty, Teradyne, and Salesforce on8, 2026.
CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results